These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 14613131

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Selective estrogen-receptor modulators (SERMs) in the cyclopentadienylrhenium tricarbonyl series: synthesis and biological behaviour.
    Top S, Vessières A, Pigeon P, Rager MN, Huché M, Salomon E, Cabestaing C, Vaissermann J, Jaouen G.
    Chembiochem; 2004 Aug 06; 5(8):1104-13. PubMed ID: 15300835
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Role of aromatic substituents on the antiproliferative effects of diphenyl ferrocenyl butene compounds.
    Zekri O, Hillard EA, Top S, Vessières A, Pigeon P, Plamont MA, Huché M, Boutamine S, McGlinchey MJ, Müller-Bunz H, Jaouen G.
    Dalton Trans; 2009 Jun 14; (22):4318-26. PubMed ID: 19662309
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains.
    Nguyen A, Top S, Pigeon P, Vessières A, Hillard EA, Plamont MA, Huché M, Rigamonti C, Jaouen G.
    Chemistry; 2009 Jun 14; 15(3):684-96. PubMed ID: 19053086
    [Abstract] [Full Text] [Related]

  • 6. Modification of the estrogenic properties of diphenols by the incorporation of ferrocene. Generation of antiproliferative effects in vitro.
    Vessières A, Top S, Pigeon P, Hillard E, Boubeker L, Spera D, Jaouen G.
    J Med Chem; 2005 Jun 16; 48(12):3937-40. PubMed ID: 15943467
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The presence of a ferrocenyl unit on an estrogenic molecule is not always sufficient to generate in vitro cytotoxicity.
    Vessières A, Spera D, Top S, Misterkiewicz B, Heldt JM, Hillard E, Huché M, Plamont MA, Napolitano E, Fiaschi R, Jaouen G.
    ChemMedChem; 2006 Nov 16; 1(11):1275-81. PubMed ID: 17022106
    [Abstract] [Full Text] [Related]

  • 9. Tamoxifen derivatives for delivery of the antitumoral (DACH)Pt group: selective synthesis by McMurry coupling, and biochemical behaviour.
    Top S, Kaloun el B, Vessières A, Leclercq G, Laïos I, Ourevitch M, Deuschel C, McGlinchey MJ, Jaouen G.
    Chembiochem; 2003 Aug 04; 4(8):754-61. PubMed ID: 12898627
    [Abstract] [Full Text] [Related]

  • 10. Organometallic cyclic polyphenols derived from 1,2-(alpha-keto tri or tetra methylene) ferrocene show strong antiproliferative activity on hormone-independent breast cancer cells.
    Plazuk D, Top S, Vessières A, Plamont MA, Huché M, Zakrzewski J, Makal A, Woźniak K, Jaouen G.
    Dalton Trans; 2010 Aug 28; 39(32):7444-50. PubMed ID: 20614088
    [Abstract] [Full Text] [Related]

  • 11. The influence of phenolic hydroxy substitution on the electron transfer and anti-cancer properties of compounds based on the 2-ferrocenyl-1-phenyl-but-1-ene motif.
    Hillard EA, Pigeon P, Vessières A, Amatore C, Jaouen G.
    Dalton Trans; 2007 Nov 21; (43):5073-81. PubMed ID: 17992292
    [Abstract] [Full Text] [Related]

  • 12. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J, Bischoff SF, Buhl T, Floersheim P, Fournier B, Geiser M, Halleux C, Kallen J, Keller H, Ramage P.
    J Med Chem; 2005 Jan 27; 48(2):364-79. PubMed ID: 15658851
    [Abstract] [Full Text] [Related]

  • 13. A series of unconjugated ferrocenyl phenols: prospects as anticancer agents.
    Hillard E, Vessières A, Le Bideau F, Plazuk D, Spera D, Huché M, Jaouen G.
    ChemMedChem; 2006 May 27; 1(5):551-9. PubMed ID: 16892391
    [Abstract] [Full Text] [Related]

  • 14. Investigations on the effects of basic side chains on the hormonal profile of (4R,5S)/(4S,5R)-4,5-bis(4-hydroxyphenyl)-2-imidazolines.
    von Rauch M, Busch S, Gust R.
    J Med Chem; 2005 Jan 27; 48(2):466-74. PubMed ID: 15658860
    [Abstract] [Full Text] [Related]

  • 15. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
    Murphy CS, Parker CJ, McCague R, Jordan VC.
    Mol Pharmacol; 1991 Mar 27; 39(3):421-8. PubMed ID: 2005879
    [Abstract] [Full Text] [Related]

  • 16. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
    Power KA, Thompson LU.
    Breast Cancer Res Treat; 2003 Oct 27; 81(3):209-21. PubMed ID: 14620916
    [Abstract] [Full Text] [Related]

  • 17. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
    Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, Burdette JE, Bolton JL.
    Chem Res Toxicol; 2003 Jul 27; 16(7):832-7. PubMed ID: 12870885
    [Abstract] [Full Text] [Related]

  • 18. Reactivity and antiproliferative activity of ferrocenyl-tamoxifen adducts with cyclodextrins against hormone-independent breast-cancer cell lines.
    Buriez O, Heldt JM, Labbé E, Vessières A, Jaouen G, Amatore C.
    Chemistry; 2008 Jul 27; 14(27):8195-203. PubMed ID: 18668496
    [Abstract] [Full Text] [Related]

  • 19. Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects.
    Vessières A, Top S, Beck W, Hillard E, Jaouen G.
    Dalton Trans; 2006 Jan 28; (4):529-41. PubMed ID: 16402138
    [Abstract] [Full Text] [Related]

  • 20. Preparation and evaluation of carborane analogues of tamoxifen.
    Beer ML, Lemon J, Valliant JF.
    J Med Chem; 2010 Nov 25; 53(22):8012-20. PubMed ID: 21028825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.